Smooth Muscle Actin and S100p on Non Germinal Centre Diffuse Large B Cell Lymphoma Are Adverse Prognostic Factors: Pilot Study

Overview

Journal Diagn Pathol

Publisher Biomed Central

Specialty Pathology

Date 2007 Mar 6

PMID 17335572

Citations 4

Authors

Howayda Abd El All

Affiliations

Soon will be listed here.

Abstract

Introduction: The expression of smooth muscle actin (SMA) and s100p has been identified on an aggressive retro-orbital diffuse large B cell lymphoma (DLBCL) 1.

Aim: To assess the prognostic significance of immunohistochemical (IHC) expression of SMA and s100p on DLBCL.

Materials And Methods: Twenty nine cases diagnosed as DLBCL were first classified into germinal centre (GC) B cell like and non GC origin either activated B cells (ABC) or type 3 based on their immunoreactivity for CD10, bcl-6 and Mum-1. Bcl-2 and MIB-1 as adverse prognostic factors were assessed. SMA and s100p were evaluated and correlated with patients' clinicopathological characteristics.

Results: Eleven cases (37.93%) positive for CD10 and/or bcl-6 were classified as GC B cell like subtype, 7 cases positive only for Mum-1 as ABC subtype (24.14%), and 11 cases double positive or negative for bcl-6 and Mum-1 were considered as type 3 (37.93%). Nuclear and cytoplasmic SMA and s100p were expressed in 58.62% and 51.72% of cases respectively and were strongly associated with the non GC like phenotype (p < 0.001 for SMA and p < 0.01 for s100p). SMA and s100p were strongly related to each other (p < 0.001). SMA was closely associated with bcl-2 and MIB-1 (p < 0.01 and p < 0.025 respectively), while s100p was only associated with bcl-2 (p < 0.05).

Conclusion: SMA and s100p are expressed on non GC DLBCL and appear to be adverse prognostic factors. Future large studies evaluating their significance will be valuable to assess the different subgroups in clinical context. Lastly, this expression may lead to misdiagnosis of non hematopoeitic neoplasm if lymphoid markers are not included in the IHC panel.

Citing Articles

Down-regulation of S100P induces apoptosis in endometrial epithelial cell during GnRH antagonist protocol.

Zhang D, Han M, Zhou M, Liu M, Li Y, Xu B Reprod Biol Endocrinol. 2021; 19(1):99.

PMID: 34215278 PMC: 8252288. DOI: 10.1186/s12958-021-00787-0.

PAX8 Distinguishes Diffuse Large B-Cell Lymphoma Mimicking Sarcoma.

Hirsch M, Nascimento A Case Rep Pathol. 2017; 2017:6714549.

PMID: 28634564 PMC: 5467342. DOI: 10.1155/2017/6714549.

S100P expression is a novel prognostic factor in hepatocellular carcinoma and predicts survival in patients with high tumor stage or early recurrent tumors.

Yuan R, Chang K, Chen Y, Hsu H, Lee P, Lai P PLoS One. 2013; 8(6):e65501.

PMID: 23785431 PMC: 3681902. DOI: 10.1371/journal.pone.0065501.

S100P expression in response to sex steroids during the implantation window in human endometrium.

Zhang D, Ma C, Sun X, Xia H, Zhang W Reprod Biol Endocrinol. 2012; 10:106.

PMID: 23216986 PMC: 3551790. DOI: 10.1186/1477-7827-10-106.

References

Zhu X, Zeng X, Huang B, Hao S . Actin is closely associated with RNA polymerase II and involved in activation of gene transcription. Biochem Biophys Res Commun. 2004; 321(3):623-30. DOI: 10.1016/j.bbrc.2004.05.229. View

Dong J, Chong Y, Meyerson H . Hepatosplenic alpha beta T-cell lymphoma: a report of an S100-positive case. Arch Pathol Lab Med. 2003; 127(3):e119-22. DOI: 10.5858/2003-127-e119-HTLARO. View

Philip P . Distribution of actin content in human B and T lymphocytes by DNAse 1 inhibition test. Immunol Lett. 1983; 7(2):81-4. DOI: 10.1016/0165-2478(83)90038-x. View

Stark R, Liebes L, Nevrla D, Conklyn M, Silber R . Decreased actin content of lymphocytes from patients with chronic lymphocytic leukemia. Blood. 1982; 59(3):536-41. View

Takeshita H, Kusuzaki K, Ashihara T, Gebhardt M, Mankin H, Hirasawa Y . Actin organization associated with the expression of multidrug resistant phenotype in osteosarcoma cells and the effect of actin depolymerization on drug resistance. Cancer Lett. 1998; 126(1):75-81. DOI: 10.1016/s0304-3835(97)00539-9. View

Wang J, Sun N, Nozawa Y, Arber D, Chu P, Chang K . Histological and immunohistochemical characterization of extranodal diffuse large-cell lymphomas with prominent spindle cell features. Histopathology. 2001; 39(5):476-81. DOI: 10.1046/j.1365-2559.2001.01271.x. View

Dogan A, Bagdi E, Munson P, Isaacson P . CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol. 2000; 24(6):846-52. DOI: 10.1097/00000478-200006000-00010. View

Iqbal J, Neppalli V, Wright G, Dave B, Horsman D, Rosenwald A . BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24(6):961-8. DOI: 10.1200/JCO.2005.03.4264. View

Miller T, Grogan T, Dahlberg S, Spier C, Braziel R, Banks P . Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood. 1994; 83(6):1460-6. View

10.

Hans C, Weisenburger D, Greiner T, Gascoyne R, Delabie J, Ott G . Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2003; 103(1):275-82. DOI: 10.1182/blood-2003-05-1545. View

11.

Chan J, Ng C, Chu Y, Wong K . S-100 protein-positive sinusoidal large cell lymphoma. Hum Pathol. 1987; 18(7):756-9. DOI: 10.1016/s0046-8177(87)80251-4. View

12.

Ruco L, Stoppacciaro A, Barsotti P, Vitolo D, Mirolo M, Cassano A . S-100+ lymph node neoplasm. Report of a case with histological AL and immunological features intermediate between T cell lymphoma and malignant histiocytosis. Virchows Arch A Pathol Anat Histopathol. 1984; 404(4):351-8. DOI: 10.1007/BF00695219. View

13.

Gettemans J, Van Impe K, Delanote V, Hubert T, Vandekerckhove J, De Corte V . Nuclear actin-binding proteins as modulators of gene transcription. Traffic. 2005; 6(10):847-57. DOI: 10.1111/j.1600-0854.2005.00326.x. View

14.

Olave I, Reck-Peterson S, Crabtree G . Nuclear actin and actin-related proteins in chromatin remodeling. Annu Rev Biochem. 2002; 71:755-81. DOI: 10.1146/annurev.biochem.71.110601.135507. View

15.

Liebes L, Stark R, Nevrla D, Grusky G, Zucker-Franklin D, Silber R . Purification and characterization of actin from normal and chronic lymphocytic leukemia lymphocytes. Cancer Res. 1983; 43(10):4966-73. View

16.

Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V . Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005; 106(9):3183-90. PMC: 1895326. DOI: 10.1182/blood-2005-04-1399. View

17.

Hanson C, Bockenstedt P, Schnitzer B, Fox D, Kueck B, Braun D . S100-positive, T-cell chronic lymphoproliferative disease: an aggressive disorder of an uncommon T-cell subset. Blood. 1991; 78(7):1803-13. View

18.

Owen M, Auger J, Barber B, Edwards A, Walsh F, Crumpton M . Actin may be present on the lymphocyte surface. Proc Natl Acad Sci U S A. 1978; 75(9):4484-8. PMC: 336140. DOI: 10.1073/pnas.75.9.4484. View

19.

Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-11. DOI: 10.1038/35000501. View

20.

Rosenwald A, Wright G, Chan W, Connors J, Campo E, Fisher R . The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(25):1937-47. DOI: 10.1056/NEJMoa012914. View